

## Evonik invests into technical upgrade of European methionine Verbund

18 March 2025

- Evonik is investing a low double-digit million euro amount in its European methionine Verbund Antwerp/Wesseling
- Technical upgrades will improve process efficiency, reliability and sustainability of Evonik's production of DL-methionine
- Measures require a partial shutdown of production facilities for 8–10 weeks in the period May to July 2025

**Main press contact**

**Yama Olumi**  
Head of Market Communications  
Animal Nutrition  
Phone + 49 6181 59-12437  
yama.olumi@evonik.com

**Alternative press contact**

**Dr. Jürgen Krauter**  
Head of Market Communications  
Evonik  
Phone +49 6181 59-6847  
juergen.krauter@evonik.com

**Essen, Germany.** Evonik is continuing to optimize its global production setup for MetAMINO® (DL-methionine) with a technical upgrade of its European methionine Verbund Antwerp (Belgium)/Wesseling (Germany). The low double-digit million euro investment requires a partial shutdown of these facilities for 8–10 weeks in the period May to July 2025. All existing contracts and supply agreements will be honored.

“We are constantly working to further increase the process efficiency, reliability and sustainability of our three global methionine production hubs. This is how we remain competitive and ensure highest possible supply security for our customers,” said Dr. Dirk Hoehler, head of the amino acids business of Evonik's Animal Nutrition business line.

Measures to increase process efficiency and reliability include a new process control system and a new bagging station. Various technical improvements will contribute to reduce nitrogen, sulfur, and CO<sub>2</sub> emissions. Hoehler: “To reduce our ecological footprint is an ongoing, strong motivation for us. We are committed to the strictest European sustainability requirements.”

Evonik is the only global player in methionine that serves growing global feed markets from three world-scale production hubs in three regions of the world: Antwerp/Wesseling, Mobile (Alabama, USA), and Singapore. In the last three years, Evonik has invested over €200 million in expanding its methionine facilities in

**Evonik Industries AG**  
Rellinghauser Straße 1-11  
45128 Essen  
Germany  
Phone +49 201 177-01  
www.evonik.com

Supervisory Board  
Bernd Tönjes, Chairman  
Executive Board  
Christian Kullmann, Chairman  
Dr. Harald Schwager, Deputy Chairman  
Maike Schuh, Thomas Wessel

Registered Office is Essen  
Register Court Essen Local Court  
Commercial Registry B 19474

Singapore and in the backward integration of methionine production in Mobile.

MetAMINO® is used in livestock production to feed animals healthily, efficiently, and sustainably. With its science-based approach, the Animal Nutrition business line of Evonik develops products, services and system solutions that help supply a growing world population with healthy, high-quality and affordable animal protein.

#### **Company information**

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.2 billion and an operating profit (adjusted EBITDA) of €2.1 billion in 2024. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 32,000 employees work together for a common purpose: We want to improve life today and tomorrow.

#### **About Nutrition & Care**

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.76 billion in 2024 with more than 5,500 employees.

#### **Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.